Post by IQVIA

Despite the proliferation of advanced monotherapies, many immunology indications have hit a therapeutic ceiling. This blog examines the scientific and strategic rationale behind advanced therapy combinations, highlighting what innovators and decision makers should consider next. Read here for more insights https://bit.ly/4eoAKAz